- Home
- IMSR vs CRBP Comparison
IMSR vs CRBP Comparison
Compare IMSR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMSR
- CRBP
- Stock Information
- Founded
- IMSR 2013
- CRBP 2009
- Country
- IMSR United States
- CRBP United States
- Employees
- IMSR N/A
- CRBP N/A
- Industry
- IMSR
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- IMSR
- CRBP Health Care
- Exchange
- IMSR Nasdaq
- CRBP Nasdaq
- Market Cap
- IMSR 233.8M
- CRBP 210.8M
- IPO Year
- IMSR N/A
- CRBP N/A
- Fundamental
- Price
- IMSR $8.09
- CRBP $11.22
- Analyst Decision
- IMSR
- CRBP Strong Buy
- Analyst Count
- IMSR 0
- CRBP 9
- Target Price
- IMSR N/A
- CRBP $48.38
- AVG Volume (30 Days)
- IMSR 1.8M
- CRBP 539.3K
- Earning Date
- IMSR 01-01-0001
- CRBP 11-12-2025
- Dividend Yield
- IMSR N/A
- CRBP N/A
- EPS Growth
- IMSR N/A
- CRBP N/A
- EPS
- IMSR N/A
- CRBP N/A
- Revenue
- IMSR $123,320.00
- CRBP N/A
- Revenue This Year
- IMSR N/A
- CRBP N/A
- Revenue Next Year
- IMSR N/A
- CRBP $220.00
- P/E Ratio
- IMSR N/A
- CRBP N/A
- Revenue Growth
- IMSR 1234.25
- CRBP N/A
- 52 Week Low
- IMSR $8.65
- CRBP $4.64
- 52 Week High
- IMSR $31.50
- CRBP $20.56
- Technical
- Relative Strength Index (RSI)
- IMSR N/A
- CRBP 38.90
- Support Level
- IMSR N/A
- CRBP $10.88
- Resistance Level
- IMSR N/A
- CRBP $12.43
- Average True Range (ATR)
- IMSR 0.00
- CRBP 0.76
- MACD
- IMSR 0.00
- CRBP 0.05
- Stochastic Oscillator
- IMSR 0.00
- CRBP 51.59
About IMSR Terrestrial Energy Inc. Common Stock
Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.